|
| 37208237 | Management of Lymph Node-positive Penile Cancer: A Systematic Review. | Eur Urol | 2024 |
| 37517601 | Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study. | Int J Radiat Oncol Biol Phys | 2024 |
| 37608154 | Turning up the heat: CTLA4 blockade in urothelial cancer. | Nat Rev Urol | 2024 |
| 37972345 | Reply to Y.-N. Feng et al. | J Clin Oncol | 2024 |
| 37460757 | Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. | Nat Med | 2024 |
| 36240478 | FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression. | J Clin Oncol | 2023 |
| 37487169 | Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial. | J Clin Oncol | 2023 |
| 37727793 | The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition. | Front Immunol | 2023 |
| 37870949 | Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. | N Engl J Med | 2023 |
| 37119523 | Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. | Cancer Med | 2023 |
| 36944799 | Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. | Nat Med | 2023 |
| 37265341 | Recent developments in perioperative combination therapy in muscle-invasive bladder cancer. | Curr Opin Urol | 2023 |
| 37030606 | A Prospective Study of Chemoradiotherapy as Primary Treatment in Patients With Locoregionally Advanced Penile Carcinoma. | Int J Radiat Oncol Biol Phys | 2023 |
| 36748180 | Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy. | BJU Int | 2023 |
| 36907692 | Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17]. | Eur Urol | 2023 |
| 36906413 | European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update. | Eur Urol | 2023 |
| 36732628 | High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. | Nat Med | 2023 |
| 36865297 | Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients. | medRxiv | 2023 |
| 36210214 | Re: Neoadjuvant PD-L1 plus CTLA-4 Blockade in Patients with Cisplatin-ineligible Operable High-risk Urothelial Carcinoma. | Eur Urol | 2023 |
| 35965206 | Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer. | Eur Urol | 2023 |
| 34535437 | Overall Survival of Patients Receiving Cisplatin or Carboplatin for Primary Metastatic Urothelial Carcinoma of the Bladder: A Contemporary Dutch Nationwide Cohort Study. | Eur Urol Focus | 2022 |
| 35641377 | Corrigendum to: Mechanistic target of rapamycin (mTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. | Urol Oncol | 2022 |
| 35577646 | Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. | Eur Urol | 2022 |
| 35603905 | Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer. | Int J Cancer | 2022 |
| 35815942 | Reply to: Comments on "Neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer". | Int J Cancer | 2022 |
| 35388003 | Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. | Nat Commun | 2022 |
| 35929803 | Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer. | Cancer Discov | 2022 |
| 35016887 | A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer. | Clin Genitourin Cancer | 2022 |
| 34861372 | Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Ann Oncol | 2022 |
| 34906411 | Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. | Urol Oncol | 2022 |
| 35086719 | Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. | Eur Urol | 2022 |
| 35029306 | Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy. | Br J Clin Pharmacol | 2022 |
| 32938232 | PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. | Future Oncol | 2021 |
| 33547461 | Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. | Nat Med | 2021 |
| 33902955 | Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial. | Eur Urol | 2021 |
| 33612455 | Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. | Eur Urol Oncol | 2021 |
| 33889546 | Development of a Prognostic AI-Monitor for Metastatic Urothelial Cancer Patients Receiving Immunotherapy. | Front Oncol | 2021 |
| 33835866 | Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice. | J Urol | 2021 |
| 33721560 | Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. | Lancet Oncol | 2021 |
| 34987518 | The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer. | Front Immunol | 2021 |
| 33991512 | Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EVâ¿¿201): a multicentre, single-arm, phase 2 trial. | Lancet Oncol | 2021 |
| 34211036 | A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer. | Sci Rep | 2021 |
| 34006553 | Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the 'trials within cohorts' study ProBCI. | BMJ Open | 2021 |
| 33168461 | Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. | Eur Urol Focus | 2021 |
| 32405063 | High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. | Nat Med | 2020 |
| 31699525 | Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. | Eur Urol | 2020 |
| 31753727 | Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. | Lancet Oncol | 2020 |
| 31895078 | Management of the penile squamous cell carcinoma patient after node positive radical inguinal lymph node dissection: current evidence and future prospects. | Curr Opin Urol | 2020 |
| 31823654 | ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer. | Future Oncol | 2020 |
| 33316557 | Utilization of systemic treatment for metastatic bladder cancer in everyday practice: Results of a nation-wide population-based cohort study. | Cancer Treat Res Commun | 2020 |